Jing ZF, Liu J, Hu R, Yan JH, Luo M. Bailing capsules for treatment of proteinuria in patients with chronic nephritis (liver and kidney Yin deficiency).
Shijie Huaren Xiaohua Zazhi 2014;
22:1592-1596. [DOI:
10.11569/wcjd.v22.i11.1592]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM: To explore the effect of Bailing capsules in the treatment of proteinuria in patients with chronic nephritis (liver and kidney Yin deficiency).
METHODS: Eighty-four chronic nephritis patients with proteinuria were randomly divided into either an experimental group or a control group. The control group was treated by tripterysium glycosides, perindopril tablets and Warfarin sodium tablets, while the experimental group was additionally given Bailing capsules on the basis of the treatments for the control group. The clinical effects, symptom score, blood pressure, ALB, and the improvement of 24 h urinary protein quantity (UPQ) were compared between the two groups.
RESULTS: The response rate in the experimental group was significantly better than that in the control group (61.90% vs 40.48%, P < 0.05). The scores of various symptoms in the experimental group after treatment were significantly lower than those before treatment (1.47 ± 0.42 vs 3.60 ± 0.96, 1.93 ± 0.48 vs 3.60 ± 1.02, 1.93 ± 0.46 vs 3.13 ± 0.96, 1.80 ± 0.40 vs 3.20 ± 0.88, 1.27 ± 0.38 vs 2.27 ± 0.75, P < 0.05). There were no significant differences in the dysphoria with feverish sensation in chest, tidal fever and night sweating, the score of dry eyes or the score of blurring of visiona between before and after treatment in the control group (2.87 ± 0.59 vs 3.33 ± 1.01, 2.80 ± 0.52 vs 3.20 ± 0.91, P > 0.05). Edema, dysphoria with feverish sensation in chest, tidal fever and night sweating, the score of dry eyes and the score of blurring of vision in the experimental group were significantly lower than those in the control group (1.47 ± 0.42 vs 2.27 ± 0.58, 1.93 ± 0.48 vs 2.87 ± 0.59, 1.80 ± 0.40 vs 2.80 ± 0.52, P < 0.05). The levels of blood pressure and 24hUPQ were significantly lower (77.13 ± 6.12 vs 86.79 ± 16.88, 0.59 ± 0.31 vs 2.06 ± 0.60, 81.16 ± 7.08 vs 85.68 ± 16.95, 0.98 ± 0.68 vs 2.07 ± 0.64, P < 0.05) and the levels of ALB (36.83 ± 10.62 vs 30.18 ± 6.77, 33.27 ± 7.11 vs 30.20 ± 6.59, P < 0.05) were significantly higher after treatment in the two groups compared with pretreatment values. The levels of blood pressure and 24hUPQ in the experimental group were significantly lower than those in the control group (77.13 ± 6.12 vs 81.16 ± 7.08, 0.59 ± 0.31 vs 0.98 ± 0.68, P < 0.05), and the levels of ALB in the experimental group were significantly higher than those in the control group (36.83 ± 10.62 vs 33.27 ± 7.11, P < 0.05).
CONCLUSION: Bailing capsules can improve clinical symptoms and urine protein levels in chronic nephritis patients with proteinuria on the basis of conventional treatments.
Collapse